Already a member? Sign in
Trileptal is a brand name for the drug oxcarbazepine. It is an anticonvulsant used to treat certain types of seizures in people who have epilepsy. It works by decreasing abnormal excitement in the brain.
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| Epilepsy | 88 | 31 |
|
|
|
|
|
| Treat my mood condition(s) | 48 | 16 |
|
|
|
|
|
| Pain | 17 | 5 |
|
|
|
|
|
| Trigeminal neuralgia (trigeminal nerve pain) | 15 | 3 |
|
|
|||
| Other | 14 | 1 |
|
||||
| Bipolar Disorder | 11 | 5 |
|
|
|
See all 206 patients currently taking Trileptal
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Trileptal
| Dry mouth (xerostomia) | 8 | |
|---|---|---|
| Excessive daytime sleepiness (somnolence) | 6 | |
| Stomach upset | 5 | |
| Lack of concentration | 5 | |
| Dizziness | 5 | |
| Drowsiness | 4 | |
| See all 76 reported side effects ▼ | ||
Frequently reported dosages based on patients currently taking Trileptal. See all 29 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Side effects too severe | 33 | ||
| Did not seem to work | 32 | ||
| Doctor's advice | 27 | ||
| Other | 15 | ||
| Personal research | 3 | ||
| Course of treatment ended | 3 | ||
| Change in health plan coverage | 2 | ||
| Expense | 1 |
Adherence
Taking treatment as prescribed
Adherence of Trileptal
Always |
65 | 77% |
|
|---|---|---|---|
Usually |
13 | 15% |
|
Sometimes |
4 | 5% |
|
Never |
2 | 2% |
|
Burden
Difficulty being on treatment
Burden of Trileptal
Very |
4 | 5% |
|
|---|---|---|---|
Somewhat |
11 | 13% |
|
A little |
14 | 17% |
|
Not at all |
55 | 65% |
|
Cost
Paid out of pocket
Cost of Trileptal
$200+ |
2 | 4% |
|
|---|---|---|---|
$100-199 |
3 | 6% |
|
$50-99 |
5 | 9% |
|
$25-49 |
5 | 9% |
|
< $25 |
38 | 72% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on February 11, 2012.